NASDAQ:CHFS

CHF Solutions Competitors

$5.42
+0.18 (+3.44 %)
(As of 04/14/2021 03:22 PM ET)
Add
Compare
Today's Range
$5.28
Now: $5.42
$5.56
50-Day Range
$5.35
MA: $6.75
$8.97
52-Week Range
$5.14
Now: $5.42
$37.50
Volume15,243 shs
Average Volume484,554 shs
Market Capitalization$32.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55

Competitors

CHF Solutions (NASDAQ:CHFS) Vs. MDT, VAR, MASI, LIVN, CNMD, and INMD

Should you be buying CHFS stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to CHF Solutions, including Medtronic (MDT), Varian Medical Systems (VAR), Masimo (MASI), LivaNova (LIVN), CONMED (CNMD), and InMode (INMD).

CHF Solutions (NASDAQ:CHFS) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and Medtronic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CHF Solutions00103.00
Medtronic031812.91

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. Medtronic has a consensus price target of $124.2692, suggesting a potential upside of 0.41%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than Medtronic.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CHF Solutions and Medtronic's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CHF Solutions$5.51 million5.79$-18,110,000.00($279.28)-0.02
Medtronic$28.91 billion5.77$4.79 billion$4.5926.97

Medtronic has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares CHF Solutions and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CHF Solutions-254.26%-173.61%-131.01%
Medtronic12.69%9.71%5.30%

Summary

Medtronic beats CHF Solutions on 10 of the 15 factors compared between the two stocks.

CHF Solutions (NASDAQ:CHFS) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and Varian Medical Systems, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CHF Solutions00103.00
Varian Medical Systems35001.63

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. Varian Medical Systems has a consensus price target of $159.3571, suggesting a potential downside of 10.02%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than Varian Medical Systems.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. Comparatively, 87.0% of Varian Medical Systems shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 0.8% of Varian Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CHF Solutions and Varian Medical Systems' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CHF Solutions$5.51 million5.79$-18,110,000.00($279.28)-0.02
Varian Medical Systems$3.17 billion5.13$269.20 million$3.9145.29

Varian Medical Systems has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Profitability

This table compares CHF Solutions and Varian Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CHF Solutions-254.26%-173.61%-131.01%
Varian Medical Systems8.50%18.45%8.08%

Summary

Varian Medical Systems beats CHF Solutions on 9 of the 14 factors compared between the two stocks.

CHF Solutions (NASDAQ:CHFS) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and Masimo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CHF Solutions00103.00
Masimo02502.71

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. Masimo has a consensus price target of $272.20, suggesting a potential upside of 14.69%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than Masimo.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. Comparatively, 81.6% of Masimo shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 11.5% of Masimo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CHF Solutions and Masimo's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CHF Solutions$5.51 million5.79$-18,110,000.00($279.28)-0.02
Masimo$937.84 million14.06$196.22 million$3.2274.09

Masimo has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Masimo has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares CHF Solutions and Masimo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CHF Solutions-254.26%-173.61%-131.01%
Masimo20.30%15.75%13.12%

Summary

Masimo beats CHF Solutions on 11 of the 14 factors compared between the two stocks.

CHF Solutions (NASDAQ:CHFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and LivaNova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CHF Solutions00103.00
LivaNova04202.33

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. LivaNova has a consensus price target of $69.3333, suggesting a potential downside of 15.99%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than LivaNova.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. Comparatively, 89.1% of LivaNova shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CHF Solutions and LivaNova's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CHF Solutions$5.51 million5.79$-18,110,000.00($279.28)-0.02
LivaNova$1.08 billion3.70$-155,180,000.00$3.0826.75

CHF Solutions has higher earnings, but lower revenue than LivaNova. CHF Solutions is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Profitability

This table compares CHF Solutions and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CHF Solutions-254.26%-173.61%-131.01%
LivaNova-21.88%5.55%3.07%

CHF Solutions (NASDAQ:CHFS) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares CHF Solutions and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CHF Solutions-254.26%-173.61%-131.01%
CONMED0.04%9.48%3.75%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and CONMED, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CHF Solutions00103.00
CONMED02402.67

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. CONMED has a consensus price target of $104.60, suggesting a potential downside of 20.56%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than CONMED.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Valuation and Earnings

This table compares CHF Solutions and CONMED's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CHF Solutions$5.51 million5.79$-18,110,000.00($279.28)-0.02
CONMED$955.10 million3.98$28.62 million$2.6449.71

CONMED has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 5.4% of CONMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

CONMED beats CHF Solutions on 8 of the 13 factors compared between the two stocks.

CHF Solutions (NASDAQ:CHFS) and InMode (NASDAQ:INMD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.

Profitability

This table compares CHF Solutions and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CHF Solutions-254.26%-173.61%-131.01%
InMode32.57%28.56%24.14%

Analyst Ratings

This is a breakdown of recent ratings for CHF Solutions and InMode, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CHF Solutions00103.00
InMode00403.00

CHF Solutions presently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. InMode has a consensus price target of $71.50, suggesting a potential downside of 14.90%. Given CHF Solutions' higher probable upside, equities analysts clearly believe CHF Solutions is more favorable than InMode.

Volatility and Risk

CHF Solutions has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500.

Valuation & Earnings

This table compares CHF Solutions and InMode's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CHF Solutions$5.51 million5.79$-18,110,000.00($279.28)-0.02
InMode$156.36 million17.03$61.15 million$1.6052.06

InMode has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

65.1% of CHF Solutions shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 0.6% of CHF Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

InMode beats CHF Solutions on 10 of the 13 factors compared between the two stocks.

Ad MicroCapWatch
Stock to Keep an Eye On
Strong management, innovative products – this company won’t be under the radar for long

CHF Solutions Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.7$123.78+0.1%$166.66 billion$28.91 billion47.24
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.08+0.0%$16.27 billion$3.17 billion60.44
Masimo logo
MASI
Masimo
1.6$238.56+0.3%$13.22 billion$937.84 million61.96Insider Selling
LivaNova logo
LIVN
LivaNova
1.5$82.39+0.4%$3.99 billion$1.08 billion-19.16Analyst Report
News Coverage
CNMD
CONMED
1.6$131.24+0.5%$3.82 billion$955.10 million-3,281.00
InMode logo
INMD
InMode
1.5$83.30+0.6%$2.68 billion$156.36 million59.93Analyst Downgrade
Outset Medical logo
OM
Outset Medical
1.0$54.45+0.2%$2.34 billionN/A0.00Analyst Upgrade
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$33.78+2.6%$1.16 billion$27.37 million-46.27Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$28.29+3.3%$926.45 million$495.52 million-51.44
AxoGen logo
AXGN
AxoGen
1.5$19.51+0.7%$801.17 million$106.71 million-30.97News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$28.94+0.0%$792.09 million$23.60 million-20.67Increase in Short Interest
ViewRay logo
VRAY
ViewRay
1.3$4.37+1.6%$691.44 million$87.78 million-4.91
Cutera logo
CUTR
Cutera
1.3$31.04+0.7%$556.07 million$181.71 million-17.15Gap Down
Zynex logo
ZYXI
Zynex
1.8$15.36+2.1%$523.87 million$45.47 million46.55
Edap Tms logo
EDAP
Edap Tms
1.3$9.21+0.2%$267.82 million$50.23 million-153.50Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.08+3.8%$195.07 million$3.38 million-4.23Decrease in Short Interest
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.29+0.7%$137.33 millionN/A0.00News Coverage
FONR
FONAR
1.1$18.16+1.0%$117.78 million$85.69 million17.13
IRIDEX logo
IRIX
IRIDEX
0.9$7.40+1.1%$113.61 million$43.45 million-13.45Gap Down
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.24+5.4%$98.18 million$10,000.00-1.22Analyst Upgrade
Increase in Short Interest
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.23+3.3%$94.87 millionN/A-1.62Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.80+2.2%$89.20 million$2.39 million-2.28Decrease in Short Interest
Gap Up
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$16.91+3.1%$40.28 million$1.50 million-0.97Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.01+0.3%$31.03 million$6.57 million-0.01
STRR
Star Equity
0.1$3.33+0.9%$16.24 million$114.18 million-1.06
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.